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Abstract
Neoadjuvant endocrine therapy has been reported to decrease tumor size, which 
leads to increased breast conservation rates. To improve the clinical response, 
metronomic chemotherapy with endocrine therapy is a promising strategy. A mul-
ticenter phase II single- arm neoadjuvant trial with letrozole and cyclophosphamide 
was conducted. Eligibility criteria included postmenopausal status, T2–4 N0–1, and 
estrogen receptor- positive breast carcinoma. Letrozole (2.5 mg) plus cyclophos-
phamide (50 mg) was given orally once a day for 24 weeks. The primary endpoint 
was the clinical response rate (CRR). To investigate anti- angiogenic effects, circu-
lating endothelial cells (CECs) were quantified using the CellSearch system. From 
October 2007 to March 2010, 41 patients were enrolled. The CRR was 67.5% 
(52.0–80.0%), which was above the prespecified threshold (65%). The conversion 
rate from total mastectomy to breast- conserving surgery was 64% (18/28). Grade 
3 or greater nonhematological toxicity was not reported. Clinical response was 
associated with improved disease- free survival (DFS) (P = 0.020). The increase in 
CEC counts at 8 weeks was observed in nonresponders (P = 0.004) but not in 
responders. Patients with higher CEC counts at baseline or post- treatment showed 
worse DFS than those with lower counts (P < 0.001 at baseline and = 0.014 post- 
treatment). Multivariate analysis showed that post- treatment CEC counts but not 
pretreatment counts were independently correlated with DFS (P = 0.046). In con-
clusion, neoadjuvant letrozole plus cyclophosphamide showed a good clinical re-
sponse for postmenopausal patients with estrogen receptor- positive breast cancer. 
CEC quantification is a promising tool for treatment monitoring and prognostic 
stratification for metronomic therapy following validation of our results in larger 
studies. Clinical trial registration number: UMIN000001331 Phase II study of neo-
adjuvant letrozole combined with low- dose metronomic cyclophosphamide for 
postmenopausal women with endocrine- responsive breast cancer (JBCRG- 07)
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Introduction
Neoadjuvant endocrine therapy (NET) is one of the treat-
ment options for postmenopausal patients with endocrine- 
responsive breast cancer. NET has been reported to result 
in decreased tumor size and increased breast conservation 
rates [1–6]. Because endocrine therapy is associated with 
lower toxicity than chemotherapy, NET is preferable to 
neoadjuvant chemotherapy, especially in older patients 
and those with worsening performance status. In order 
to further improve surgical outcome, it is important to 
increase the NET response rate without increasing adverse 
effects. Chemo- endocrine therapy using metronomic 
chemotherapy is potentially useful in this regard.
Metronomic chemotherapy is the delivery of low doses 
of cytotoxic drugs at regular frequent intervals to avoid 
toxic side effects [7, 8]. It has been suggested to act via 
multiple mechanisms in exerting anticancer effects, includ-
ing anti- angiogenesis, antitumor immune response, and 
direct anticancer action [9]. Oral cyclophosphamide is one 
of the most commonly used metronomic agents and is 
administered alone or together with other drugs such as 
capecitabine and methotrexate [10–13]. Because metronomic 
chemotherapy shows anticancer effects via different mecha-
nisms of action without overt toxic side effects, it is a 
good candidate in combination with endocrine therapy.
The combined administration of the aromatase inhibitor 
letrozole with low- dose metronomic cyclophosphamide in 
elderly patients has been reported earlier [14]. This rand-
omized phase II trial showed an overall response rate (ORR) 
of 87.7% in patients assigned to receive letrozole plus 
cyclophosphamide, while letrozole alone showed an ORR 
of 71.9%. In addition, post- treatment expression of Ki- 67 
was significantly lower in tumors treated with the combined 
therapy than in tumors treated with letrozole alone. Thus, 
the combination of letrozole and oral cyclophosphamide 
appears effective and promising as neoadjuvant therapy.
We conducted a multicenter phase II single- arm trial 
of neoadjuvant metronomic chemo- endocrine therapy with 
letrozole and oral cyclophosphamide in Japan (Japan Breast 
Cancer Research Group- 07 trial: UMIN000001331). To 
investigate the possible role of anti- angiogenic effects in 
metronomic chemo- endocrine therapy, circulating 
endothelial cells (CECs) were quantified prior to and dur-
ing the neoadjuvant treatment, and their association with 
treatment response and prognosis was examined.
Patients and Methods
Patients
Women with previously untreated, clinical T2–4 N0–1 
and estrogen receptor (ER)- positive breast carcinoma were 
enrolled in this study. Other inclusion criteria were (1) 
postmenopausal status and age 60 years or older; (2) 0–1 
Eastern Cooperative Oncology Group performance status; 
and (3) written informed consent for participation in this 
study. Patients receiving agents that affect sex hormone 
status, such as hormone replacement therapy and ralox-
ifene, were excluded. Consecutive patients who met the 
inclusion criteria and agreed to participate in the study 
were recruited from October 2007 to March 2010. Written 
informed consent was obtained from all patients who 
participated in the study. The study conforms to the 
provisions of the Declaration of Helsinki.
Treatment
Patients received letrozole (2.5 mg) plus cyclophosphamide 
(50 mg) orally once a day for 24 weeks, and surgical 
therapy was conducted 1–4 weeks after the last admin-
istration of letrozole and cyclophosphamide. Anticipated 
surgery type before treatment and surgery type actually 
performed were compared to investigate whether preop-
erative therapy resulted in a higher breast conservation 
rate. Adverse events (AEs) were assessed in accordance 
with Common Terminology Criteria for Adverse Events 
(CTCAE) version 3.0.
No letrozole reduction was planned. Letrozole was 
planned to be interrupted when severe AEs occurred. 
Cyclophosphamide administration was delayed if the 
leukocyte count was <2000/mm3 or if the neutrophil 
count was <1000/mm3. In the event of grade 2 or greater 
cystitis and other grade 3 nonhematological AEs, cyclo-
phosphamide was interrupted and postponed until 
recovery.
Postoperative radiation therapy, chemotherapy, trastu-
zumab, and endocrine therapy were given as per institu-
tional practice.
The protocol was approved by the ethics committee 
in each institute.
Endpoints
The primary endpoint was the clinical response rate, 
assessed using calipers, ultrasound (US), or computed 
tomography (CT)/magnetic resonance imaging (MRI) dur-
ing the 24- week neoadjuvant treatment period in the 
intention- to- treat (ITT) population. Tumor response was 
evaluated in accordance with RECIST ver. 1.0 [15]. 
Secondary endpoints included pathological therapeutic 
effects, breast conservation rate, safety assessed using 
CTCAE ver. 3.0, disease- free survival (DFS), and overall 
survival (OS).
The target number of patients in the protocol was set 
at 40 based on the response rate of 88% in a previous 
2444 © 2018 The Authors. <i>Cancer Medicine</i> published by John Wiley & Sons Ltd. 
T. Ueno et al.Neoadjuvant letrozole plus cyclophosphamide 
report [14]. On the assumption that the expected response 
rate was 85%, 33 patients would be required for verifica-
tion of effectiveness under conditions of 65% threshold 
(based on NET results using letrozole alone), 5% one- 
sided significance level, and 80% detection power.
Pathological analyses
Pathological analyses were performed in a central labora-
tory. Tumor biopsy specimens before preoperative therapy 
were assessed for estrogen receptor, progesterone receptor 
(PgR), and human epidermal growth factor receptor type 
2 (HER2). ER and PgR status were defined as positive 
for tumors with 10% or more positive tumor cells. HER2 
positivity was determined as strong expression (3+) using 
immunohistochemistry or as HER2:CEP17 ratio >2.2 using 
fluorescence in situ hybridization [16]. The pathological 
response was assessed using surgical samples following 
preoperative therapy. A pathological complete response 
(pCR) was defined as no residual invasive tumor cells in 
the mammary gland and lymph nodes. Grade 2 response 
was defined as reduction in tumor cells by more than 
two- thirds (66%), and grade 1 was defined as reduction 
in tumor cells ≤ one- third (33%). The Ki- 67 labeling 
index (LI) using the MIB1 antibody (Dako, Glostrup, 
Denmark) was calculated by counting positively stained 
tumor cells per 1000 tumor cells in the hot spots.
Circulating endothelial cells
Blood samples were drawn into CellSave tubes (Veridex, 
LLC, NJ) prior to, at 8 weeks after treatment initiation, 
and at completion of the neoadjuvant treatment. Samples 
were sent to the central laboratory at Kyoto University 
where they were processed within 72 h after blood sam-
pling. All evaluations were performed without prior knowl-
edge of the patients’ clinical status. The CellSearch system 
was used for endothelial cell detection, as described previ-
ously [17–19]. In brief, magnetic separation was performed 
using anti- CD146 ferrofluids, followed by labeling with 
the nuclear stain 4,6- diamidino- 2- phenylindole (DAPI), a 
phycoerythrin- conjugated anti- CD105 antibody, and an 
allophycocyanin- conjugated anti- CD45 antibody. An addi-
tional channel was used for an anti- CD34 antibody con-
jugated to FITC (clone AC136, Miltenyi, Biotech GmbH, 
Germany). CECs were defined as CD146+CD105+ 
CD45−DAPI+ cells in this study. As CD34 is another maker 
that is positive in circulating endothelial cells, anti- CD34 
antibody was added to the additional channel [20]. A 
gray- scale charge- coupled camera device was used to scan 
the entire chamber surface, and each captured frame was 
then evaluated for objects that were potential CEC can-
didates using image analysis software.
Statistical analysis
Baseline characteristics of patients were summarized as mean 
(range) for continuous variables and number (%) for cat-
egorical variables. The clinical/pathological response rate and 
the breast conservation rate were calculated at 95% confi-
dence intervals (CIs). AEs during treatment were tabulated 
based on their CTCAE grades. OS and DFS during follow- up 
were estimated and compared using the Kaplan–Meier 
method and log- rank test between groups stratified based 
on patient characteristics and clinical/pathological outcomes 
of the neoadjuvant treatment. In biomarker analysis, asso-
ciation of CECs (as continuous variables) with clinical 
response was evaluated using univariate logistic regression 
models. The optimal cut- off value for each statistically sig-
nificant biomarker to predict clinical response was determined 
using the Youden’s index of the receiver operating charac-
teristics (ROC) curve. Patients were stratified based on the 
cut- off value into two groups, and the survival rate was 
compared between them. Multivariate survival analyses were 
performed using Cox proportional hazards models consisting 
of statistically significant variables from the survival analyses 
mentioned above. Multicollinearity was assessed using 
Spearman’s rank correlation coefficient. To address data 
sparseness, Firth’s penalized likelihood approach was applied 
in the regression analyses. A two- sided P- value below 0.05 
was considered significant. Statistical analyses were performed 
using IBM SPSS Statistics 23.0 (IBM Corp., Armonk, NY) 




From October 2007 to March 2010, 41 patients were 
enrolled in this study at four medical institutes in Japan 
(Fig. 1). One patient was excluded from the ITT popula-
tion because of entry criteria violation (tumor size <2 cm). 
Six patients were further excluded from the per- protocol 
set (PPS) due to entry criteria violation in three patients 
(higher transaminase in one, age less than 60 years in 
two patients), changing hospitals during the protocol treat-
ment in one patient, and insufficient duration (<90%) 
of drug administration in two patients. Baseline charac-
teristics of the entire population (safety population), the 
ITT population, and the PPS population are shown in 
Table 1.
Clinical and pathological response
The clinical response rate in the ITT population was 67.5% 
(52.0–80.0%), which was above the prespecified threshold 
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(65%). Associations between clinical response and baseline 
characteristics were assessed. No baseline characteristics 
including Ki- 67 LI were associated with clinical response. 
Response rates in the HER2- negative and HER2- positive 
subgroups were 60% and 80%, respectively, which showed 
no statistically significant difference.
No patients achieved pCR. Seven patients (17.5%) 
showed grade 2 pathological responses and 28 (70%) 
showed grade 1 responses.
Changes in Ki- 67 LI were assessed based on clinical 
responses (Fig. 2). Ki- 67 LI decreased after treatment in 
both responders and nonresponders, and no difference 
in the decrease was observed based on clinical response.
Surgical outcome
Among patients in the ITT population, breast- conserving 
surgery was performed in 30 patients, and the breast- 
conserving rate was 75% (30/40). Before treatment, breast- 
conserving surgery and total mastectomy were anticipated 
in 12 and 28 patients, respectively. Eighteen patients who 
were anticipated to receive mastectomy before neoadjuvant 
treatment received breast- conserving surgery. The conver-
sion rate from total mastectomy to conserving surgery 
was 64% (18/28).
Safety
Adverse events occurring in all enrolled patients are shown 
in Table 2. Twenty- two patients (54%) had leukocytopenia, 
but most (17/22) of them were grade 1. Grade 3 leuko-
cytopenia was observed in one patient. The most common 
nonhematological AE was arthralgia, which was observed 
in six patients. One patient was diagnosed with liver cancer 
3 months after initiation of the neoadjuvant treatment, 
and the causal relationship with treatment is unlikely. No 
Figure 1. CONSORT diagram of the study.




(Safety population) ITT PPS
Number of patients 41 40 34
Age





T1 1 (2.4) 0 (0.0) 0 (0.0)
T2 36 (87.8) 36 (90.0) 31 (91.2)
T3 4 (9.8) 4 (10.0) 3 (8.8)
N
N0 36 (87.8) 35 (87.5) 29 (85.3)
N1 5 (12.2) 5 (12.5) 5 (14.7)
Receptor status
ER
+ 41 (100.0) 40 (100.0) 34 (100.0)
− 0 (0.0) 0 (0.0) 0 (0.0)
PgR
+ 27 (65.9) 26 (65.0) 20 (58.8)
− 14 (34.1) 14 (35.0) 14 (41.2)
HER2
+ 9 (22.0) 9 (22.5) 5 (14.7)
− 32 (78.0) 31 (77.5) 29 (85.3)
Histological grade
1 13 (31.7) 13 (32.5) 9 (26.5)
2 26 (63.4) 25 (62.5) 24 (70.6)
3 0 (0.0) 0 (0.0) 0 (0.0)
NA 2 (4.9) 2 (5.0) 1 (2.9)
(): %
ER, estrogen receptor; ITT, intention- to- treat; PPS, per- protocol set.
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grade 3 or greater nonhematological toxicity was reported. 
No patients discontinued the treatment due to AE.
Survival analysis
Survival analyses were performed in the PPS. Among 34 
patients, postoperative chemotherapy was given to seven 
patients. The median follow- up period was 68.5 months 
(range: 18.1–86.5).
DFS at 5 years was 90.9% (95% CI: 48.4–90.4%). Three 
patients relapsed during follow- up, one with axillary lymph 
node recurrence, one with chest wall recurrence, and one 
with lung metastasis. Overall survival at 5 years was 93.9% 
(95% CI: 74.4–97.0%). Two patients died during follow-
 up, one with liver cancer and the other with myocardial 
infarction 3 years after treatment initiation. Baseline factors 
including T stage, nodal involvement, HER2 status, and 
types of surgery were not associated with DFS.
Associations of survival with clinical response and AEs 
were evaluated. Clinical response with US was associated 
with prognosis; responders showed better DFS than non-
responders (P = 0.020) (Fig. 3). Interestingly, leukocyto-
penia was associated with prognosis; patients with no or 
mild leukocytopenia (G0 or 1) had better DFS than those 
Figure 2. Change in Ki67 labeling index according to clinical response. Ki67 labeling index decreased after the treatment in both responders and 
nonresponders (P < 0.001 for both). Representative images with Ki67 staining are shown (scale bar: 50 μm).
Table 2. Adverse events.
Adverse event All grade Grade≧3
Diarrhea 1 0
Dry mouth/salivary gland 1 0
Stomatitis 1 0
Infection (cold sore) 1 0
Periodontal disease 1 0
Epigastric distress 1 0
Nausea 1 0
Anorexia 3 0
Liver cancer 1 0
Cystitis 2 0
Osteoporosis 2 0














Number of patients: 41
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with severe leukocytopenia (G2 or 3) (P = 0.003) (Fig. 3). 
No other factors including pre- and post- treatment Ki- 67 
LI, changes in Ki- 67 LI, or HER2 status were associated 
with DFS or OS.
Circulating endothelial cells
Circulating endothelial cells were quantified prior to and 
during the neoadjuvant therapy. Their association with 
clinical response with US and prognosis were 
evaluated.
In nonresponders, CEC counts were significantly 
increased at 8 weeks (P = 0.004) compared with pretreat-
ment counts, while in responders, no such increases were 
observed (P = 0.35) (Fig. 4). Similarly, CD34- positive 
CEC counts were increased at 8 weeks in nonresponders 
(P = 0.003) but not in responders (P = 0.39). Baseline 
counts of CEC and CD34- positive CEC did not correlate 
with treatment response.
The association between CEC counts and prognosis was 
evaluated. Cut- off values for CEC and CD34- positive CEC 
were determined using the Youden’s index of ROC curves. 
Baseline counts of CEC and CD34- positive CEC were 
significantly associated with DFS, and patients with higher 
counts of CEC and CD34- positive CEC showed worse 
prognosis than those with lower counts (P < 0.001 and 
P = 0.004, respectively) (Fig. 5A). In addition, post- 
treatment counts of CEC and CD34- positive CEC were 
also significantly correlated with DFS (P = 0.014 and 
P = 0.008, respectively) (Fig. 5B).
Because clinical response and leukocytopenia were also 
associated with DFS, multivariate analyses of DFS, includ-
ing clinical response, leukocytopenia, and pre- and post- 
treatment counts of CEC, were performed. Interestingly, 
post- treatment counts of CEC, but not pretreatment counts, 
were independently correlated with DFS (P = 0.046) 
(Table 3). A similar result was observed for CD34- positive 
CEC (P = 0.043) (Table 3).
Discussion
In this study, we demonstrated that neoadjuvant metro-
nomic chemo- endocrine therapy with letrozole and cyclo-
phosphamide showed a good response in Japanese 
postmenopausal women with ER- positive breast cancer, 
with a conversion rate from mastectomy to breast- 
conserving surgery of 64% and tolerable toxicity. In addi-
tion, increases in CEC counts at week 8 indicated poor 
response, and post- treatment CEC counts showed a good 
and independent prognostic value.
One of the advantages of neoadjuvant treatment is an 
increase in breast- conserving rate. The IMPAKT trial, 
which compared anastrozole, tamoxifen, and both in 
combination in the neoadjuvant setting, showed that the 
conversion rates from mastectomy to breast- conserving 
surgery were 44%, 31%, and 24%, respectively [6]. Thus, 
the conversion rate achieved in this study (64%) was 
higher than the rate in any endocrine treatment group 
of the IMPAKT trial. Another neoadjuvant endocrine study, 
the PROACT trial, compared anastrozole and tamoxifen 
[1]. Although the conversion rate was not reported, the 
improvement in surgery including the conversion from 
mastectomy to breast- conserving surgery was observed in 
38.1% and 29.9% of the patients who received anastrozole 
and tamoxifen, respectively. Altogether, these results sug-
gest that the combination of letrozole and cyclophospha-
mide would give a higher conversion rate than endocrine 
therapy alone.
In nonresponders, CEC counts increased at week 8, while 
in responders, such an increase was not observed. In our 
previous study, we showed that CEC counts done with 
the CellSearch system increased during neoadjuvant 
Figure 3. Disease- free survival according to clinical response and leukocytopenia. Better clinical response and milder leukocytopenia were associated 
with a better disease- free survival (P = 0.020 and 0.003, respectively).
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chemotherapy, especially during therapy involving taxane- 
based regimens [17]. Such increases have been suggested 
to contribute to angiogenesis and neovascularization in 
order to repair damaged tissues, including normal and 
cancerous tissues [21–23]. Metronomic chemotherapy is 
expected to prevent such a vascular rebound in neovascu-
larization, especially in tumor tissues, which is one of the 
suggested mechanisms for its anticancer effect. Therefore, 
it is conceivable that prevention of neovascularization due 
to metronomic chemotherapy led to maintained CEC counts 
in responders, while failure of such prevention resulted in 
increased CEC counts in nonresponders.
In our study, although CEC counts at both baseline 
and post- treatment showed prognostic value, only post- 
treatment CEC counts had independent prognostic power. 
Poor prognosis in patients with high post- treatment CEC 
counts may be a result of insufficient anti- angiogenic 
response with metronomic chemo- endocrine therapy. This 
result seems consistent with the prognostic value of post- 
treatment Ki- 67 LI in NET, which showed better prognostic 
power than pretreatment Ki- 67 LI [24–27]. Our results 
along with other reports suggest that biological responses, 
such as the antiproliferative response indicated by Ki- 67 
LI and anti- angiogenic response indicated by CEC counts 
after metronomic therapy, show more precise prognostic 
value than the baseline biology of tumors.
Figure 4. Change in circulating endothelial cell count and clinical 
response. Nonresponders showed an increase in circulating endothelial 
cell count at 8 weeks (P = 0.004), while responders did not (P = 0.35).
Figure 5. (A) Disease- free survival according to pretreatment CEC and CD34- positive CEC count. Higher counts of CEC and CD34- positive CEC showed 
a worse prognosis than lower counts (P < 0.001 and = 0.004, respectively). (B) Disease- free survival according to post- treatment CEC and CD34- positive 
CEC count. Higher counts of post- treatment CEC and CD34- positive CEC showed a worse prognosis (P = 0.014 and 0.008, respectively).
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Leukocytopenia was associated with prognosis in this 
study. Severe leukocytopenia (G2 or G3) was associated 
with worse DFS. This seems contradictory to results reported 
with conventional chemotherapy in adjuvant settings for 
early- stage breast cancer [28–30]. These previous studies 
indicated that severe myelosuppression was associated with 
better prognosis in patients with breast cancer receiving 
CMF (cyclophosphamide, methotrexate, and 5- fluorouracil) 
or CAF (cyclophosphamide, doxorubicin, and 
5- fluorouracil), suggesting that hematological toxicity due 
to conventional chemotherapy may represent biological 
activity of the drugs, resulting in improved prognosis. 
However, metronomic chemotherapy has been suggested 
to exert anticancer effects via different mechanisms of 
action compared to conventional chemotherapy, one of 
which is activation of antitumor immune response. Indeed, 
low- dose cyclophosphamide has been implicated in activa-
tion of innate immunity [31–33]. Therefore, myelosup-
pression during metronomic treatment may lead to 
insufficient immune activation, which might result in poor 
treatment efficacy in patients with severe leukocytopenia.
Although the objective response rate (67.5%) in our 
study appears a little lower than that (87.7%) in a previ-
ous report by Bottini et al. [14], some differences exist 
between the two studies. Bottini’s study included only 
elderly patients, and thus, median patient age in our study 
was lower in comparison. More than half of the patients 
in Bottini’s study had histological grade 3 tumors, while 
none of the patients in our study had grade 3 tumors. 
The clinical response was assessed using calipers in Bottini’s 
study, while it was assessed with calipers, US, and CT/
MRI in our study. These differences might have contrib-
uted to different response rates in the two studies.
This study was limited in terms of some parameters. 
One of its biggest limitations was its small sample size. 
Because this was a phase II trial investigating clinical efficacy 
and tolerability of combined treatment with letrozole and 
low- dose cyclophosphamide, the sample size was set at 40. 
In order to validate the clinical utility of the treatment, a 
larger study is warranted. It is also important to interpret 
the results including the prognostic analysis with this sample 
size cautiously. To confirm the prognostic value of CEC, 
it is necessary to conduct a larger study in which CECs 
are serially measured. The definition of ER and PgR posi-
tivity is another issue. In 2010, the American Society of 
Clinical Oncology/College of American Pathologists recom-
mended that ER and PgR assays be considered positive if 
there are at least 1% positive tumor nuclei in the sample 
on testing with appropriate controls [34]. Because this study 
started in 2007, the old criteria of ER and PgR were used. 
Thus, future studies to validate our results should be con-
ducted with the new definition of ER and PgR positivity. 
Another limitation was that this was a single- arm study in 
which chemo- endocrine therapy was not compared with 
either endocrine therapy alone or metronomic chemotherapy 
alone. It is, therefore, not clear whether combined admin-
istration of letrozole with metronomic cyclophosphamide 
resulted in a better outcome than letrozole or cyclophos-
phamide alone would have in this population. A randomized 
controlled study would be required for such a comparison 
in a larger confirmative study.
In conclusion, metronomic chemo- endocrine therapy 
with letrozole plus cyclophosphamide showed a good 
response and was tolerated in Japanese postmenopausal 
patients with ER- positive breast cancer. An increase in 
CEC counts during the treatment was associated with poor 
response, and post- treatment CEC counts as well as clinical 
response were independent prognostic factors. The com-
bination of letrozole and cyclophosphamide could be an 
option for postmenopausal women with ER- positive breast 
cancer. CEC quantification would be a promising tool for 
treatment monitoring and prognostic stratification following 
validation of our results in larger prospective studies.
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Bold means statistically significant.
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